Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioSig Technologies appoints Tony Zook to board of directors » 09:20
07/01/20
07/01
09:20
07/01/20
09:20
BSGM

BioSig Technologies

$7.24 /

-0.31 (-4.11%)

, AZN

AstraZeneca

$52.89 /

+ (+0.00%)

BioSig Technologies…

BioSig Technologies (BSGM) appointed Mr. Anthony Zook to its Board of Directors. Mr. Zook held several executive positions at AstraZeneca (AZN), including EVP of Global Commercial Operations from 2010 to 2013, President and CEO of the North American division from 2007 to 2010 and President of Medimmune, the wholly-owned biologics division of AstraZeneca.

ShowHide Related Items >><<
BSGM BioSig Technologies
$7.24 /

-0.31 (-4.11%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

BSGM BioSig Technologies
$7.24 /

-0.31 (-4.11%)

03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Roth Capital
BioSig Technologies initiated with a Buy at Roth Capital
AZN AstraZeneca
$52.89 /

+ (+0.00%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$52.89 /

+ (+0.00%)

  • 21
    Feb
AZN AstraZeneca
$52.89 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

BSGM BioSig Technologies
$7.24 /

-0.31 (-4.11%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

Tuesday
Options
Unusually active option classes on open June 30th » 09:40
06/30/20
06/30
09:40
06/30/20
09:40
MT

ArcelorMittal

$10.57 /

+ (+0.00%)

, ASHR

X-trackers Harvest CSI 300

$29.38 /

+ (+0.00%)

, FOXA

Fox Corp.

$26.87 /

+ (+0.00%)

, LULU

Lululemon

$293.45 /

+ (+0.00%)

, AZN

AstraZeneca

$52.89 /

+ (+0.00%)

, IDEX

Ideanomics

$2.06 /

+ (+0.00%)

, NEM

Newmont

$59.53 /

+ (+0.00%)

, MCD

McDonald's

$182.67 /

+ (+0.00%)

, UNG

United States Natural Gas Fund

$9.94 /

+ (+0.00%)

, COTY

Coty

$4.73 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: ArcelorMittal (MT), db X trackers China (ASHR), 21st Century Fox (FOXA), Lululemon (LULU), AstraZeneca (AZN), Ideanomics (IDEX), Newmont Mining (NEM), McDonald's (MCD), U.S. Natural Gas Fund (UNG), and Coty (COTY).

ShowHide Related Items >><<
NEM Newmont
$59.53 /

+ (+0.00%)

MT ArcelorMittal
$10.57 /

+ (+0.00%)

MCD McDonald's
$182.67 /

+ (+0.00%)

LULU Lululemon
$293.45 /

+ (+0.00%)

IDEX Ideanomics
$2.06 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

MT ArcelorMittal
$10.57 /

+ (+0.00%)

06/23/20 Morgan Stanley
ArcelorMittal price target lowered to EUR 13.30 at Morgan Stanley
06/22/20 Societe Generale
ArcelorMittal upgraded to Hold from Sell at Societe Generale
06/22/20 Societe Generale
ArcelorMittal upgraded to Hold from Sell at Societe Generale
05/18/20 Morgan Stanley
ArcelorMittal price target lowered to EUR 13.50 at Morgan Stanley
ASHR X-trackers Harvest CSI 300
$29.38 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

06/19/20 Macquarie
Macquarie upgrades Fox to Neutral on better ad market
06/19/20 Macquarie
Fox Corp. upgraded to Neutral from Underperform at Macquarie
06/18/20 Citi
Fox Corp. price target raised to $31 from $26 at Citi
05/28/20 Jefferies
Flutter Entertainment share sale a 'confident, proactive step,' says Jefferies
LULU Lululemon
$293.45 /

+ (+0.00%)

06/30/20 Morgan Stanley
Lululemon boosted competitive advantage with Mirror deal, says Morgan Stanley
06/30/20 MKM Partners
Lululemon's Mirror deal 'highly attractive and synergistic', says MKM Partners
06/30/20 Roth Capital
Roth boosts Peloton target to $66, says buy Mirror acquisition selloff
06/30/20 Piper Sandler
Piper Sandler favors Lululemon acquisition of Mirror
AZN AstraZeneca
$52.89 /

+ (+0.00%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
IDEX Ideanomics
$2.06 /

+ (+0.00%)

NEM Newmont
$59.53 /

+ (+0.00%)

06/29/20 Citi
Newmont price target lowered to $70 from $74 at Citi
05/18/20 Standpoint Research
Newmont downgraded to Hold from Buy at Standpoint Research
05/06/20 Deutsche Bank
Newmont price target raised to $70 from $54 at Deutsche Bank
05/06/20 Citi
Newmont price target raised to $70 from $46 at Citi
MCD McDonald's
$182.67 /

+ (+0.00%)

06/24/20 BMO Capital
McDonald's price target raised to $220 from $215 at BMO Capital
06/24/20 JPMorgan
McDonald's price target raised to $204 from $180 at JPMorgan
06/17/20 Morgan Stanley
McDonald's price target raised to $200 from $189 at Morgan Stanley
06/17/20 SunTrust
McDonald's price target raised to $208 from $195 at SunTrust
UNG United States Natural Gas Fund
$9.94 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

06/30/20 Jefferies
Jefferies says Coty 'needs to defy odds' for KKW deal to deliver sustained value
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/12/20 Deutsche Bank
Coty price target lowered to $6 from $8 at Deutsche Bank
NEM Newmont
$59.53 /

+ (+0.00%)

MCD McDonald's
$182.67 /

+ (+0.00%)

LULU Lululemon
$293.45 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

  • 12
    May
  • 13
    Dec
NEM Newmont
$59.53 /

+ (+0.00%)

MT ArcelorMittal
$10.57 /

+ (+0.00%)

MCD McDonald's
$182.67 /

+ (+0.00%)

LULU Lululemon
$293.45 /

+ (+0.00%)

IDEX Ideanomics
$2.06 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

MT ArcelorMittal
$10.57 /

+ (+0.00%)

MCD McDonald's
$182.67 /

+ (+0.00%)

LULU Lululemon
$293.45 /

+ (+0.00%)

IDEX Ideanomics
$2.06 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

UNG United States Natural Gas Fund
$9.94 /

+ (+0.00%)

NEM Newmont
$59.53 /

+ (+0.00%)

MT ArcelorMittal
$10.57 /

+ (+0.00%)

MCD McDonald's
$182.67 /

+ (+0.00%)

LULU Lululemon
$293.45 /

+ (+0.00%)

IDEX Ideanomics
$2.06 /

+ (+0.00%)

FOXA Fox Corp.
$26.87 /

+ (+0.00%)

COTY Coty
$4.73 /

+ (+0.00%)

AZN AstraZeneca
$52.89 /

+ (+0.00%)

ASHR X-trackers Harvest CSI 300
$29.38 /

+ (+0.00%)

Hot Stocks
Daxor appoints Henry Cremisi, Joy Goudie to board of directors » 08:27
06/30/20
06/30
08:27
06/30/20
08:27
DXR

Daxor

$13.06 /

+0.22 (+1.71%)

, AZN

AstraZeneca

$52.89 /

+0.19 (+0.36%)

Daxor Corporation (DXR)…

Daxor Corporation (DXR) announced the appointments of Dr. Henry D. Cremisi and Joy Goudie, Esq. to the Company's Board of Directors, effective June 29, 2020. Ms. Goudie is replacing Berne Saxe, Esq. after having served as a Board Member for 12 years. Dr. Cremisi is currently a Medical Director at AstraZeneca Pharmaceuticals (AZN) with over 32 years of experience in medicine. Joy Goudie, Esq. is currently a partner at Wissing Miller, LLP, following twelve years as Senior Patent Counsel for Revlon leading cross-functional teams in the US and Spain.

ShowHide Related Items >><<
DXR Daxor
$13.06 /

+0.22 (+1.71%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

DXR Daxor
$13.06 /

+0.22 (+1.71%)

09/30/19 Roth Capital
Daxor initiated with a Neutral at Roth Capital
07/29/19
Daxor initiated with a Buy at Maxim
07/29/19 Maxim
Daxor initiated with a Buy at Maxim
AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

Hot Stocks
AstraZeneca reports selumetinib granted orphan drug designation in Japan » 06:59
06/30/20
06/30
06:59
06/30/20
06:59
AZN

AstraZeneca

$52.89 /

+0.19 (+0.36%)

, MRK

Merck

$76.07 /

+0.9 (+1.20%)

AstraZeneca (AZN)…

AstraZeneca (AZN) announced that selumetinib has been granted orphan drug designation in Japan for the treatment of neurofibromatosis type 1, or NF1. Selumetinib is co-developed and co-commercialized with Merck (MRK), the company noted. AstraZeneca and Merck are jointly developing and commercializing selumetinib which was approved in the U.S. in April 2020 under the medicine name Koselugo for the treatment of paediatric patients two years and older with NF1 and symptomatic, inoperable PN. A marketing authorisation application in NF1 PN was accepted for review by the European Medicines Agency earlier in the year and further global regulatory submissions are underway.

ShowHide Related Items >><<
MRK Merck
$76.07 /

+0.9 (+1.20%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
MRK Merck
$76.07 /

+0.9 (+1.20%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
MRK Merck
$76.07 /

+0.9 (+1.20%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

AZN AstraZeneca
$52.89 /

+0.19 (+0.36%)

Monday
Hot Stocks
Dynavax, Moderna, Novavax COVID-19 vaccine candidates listed in WHO review » 11:10
06/29/20
06/29
11:10
06/29/20
11:10
DVAX

Dynavax

$8.77 /

-0.335 (-3.68%)

, AZN

AstraZeneca

$52.97 /

+0.27 (+0.51%)

, MRNA

Moderna

$60.91 /

-0.34 (-0.56%)

, SHTDF

Sinopharm Group

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$84.46 /

+7.1 (+9.18%)

, BNTX

BioNTech

$69.51 /

+7.14 (+11.45%)

, PFE

Pfizer

$32.57 /

+0.54 (+1.69%)

, INO

Inovio

$28.29 /

-1.555 (-5.21%)

, GSK

GlaxoSmithKline

$40.91 /

+0.35 (+0.86%)

The World Health…

The World Health Organization released landscape documents that it has prepared "for information purposes only concerning the 2019-2020 global of the novel coronavirus." WHO stated that inclusion of any particular product or entity in any of its landscape documents "does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity." Among the 17 candidate vaccines in clinical evaluation, WHO listed products under development from or in partnership with AstraZeneca (AZN), Moderna (MRNA), Sinopharm Group (SHTDF), Novavax (NVAX), BioNTech (BNTX) and Pfizer (PFE), Inovio (INO), GlaxoSmithKline (GSK) and Dynavax (DVAX), and others. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
MRNA Moderna
$60.91 /

-0.34 (-0.56%)

06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
06/12/20 Piper Sandler
Moderna preclinical data supports activity of COVID vaccine, says Piper Sandler
06/11/20 Piper Sandler
Moderna, FDA finalize Phase III trial protocol for mRNA-1273, says Piper Sandler
SHTDF Sinopharm Group
$0.00 /

+ (+0.00%)

03/19/20 Goldman Sachs
Sinopharm Group upgraded to Buy from Neutral at Goldman Sachs
NVAX Novavax
$84.46 /

+7.1 (+9.18%)

06/29/20 B. Riley FBR
Novavax price target raised to $106 from $74 at B. Riley FBR
06/29/20 H.C. Wainwright
Novavax price target raised to $101 from $50 at H.C. Wainwright
06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
INO Inovio
$28.29 /

-1.555 (-5.21%)

06/29/20 H.C. Wainwright
Inovio downgraded to Neutral from Buy at H.C. Wainwright
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 Cantor Fitzgerald
Inovio price target raised to $45 from $17 at Cantor Fitzgerald
06/26/20 Stifel
Inovio downgraded to Hold from Buy at Stifel
GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

  • 22
    May
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
  • 08
    Aug
PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

PFE Pfizer
$32.57 /

+0.54 (+1.69%)

NVAX Novavax
$84.46 /

+7.1 (+9.18%)

MRNA Moderna
$60.91 /

-0.34 (-0.56%)

INO Inovio
$28.29 /

-1.555 (-5.21%)

GSK GlaxoSmithKline
$40.91 /

+0.35 (+0.86%)

DVAX Dynavax
$8.77 /

-0.335 (-3.68%)

BNTX BioNTech
$69.51 /

+7.14 (+11.45%)

AZN AstraZeneca
$52.97 /

+0.27 (+0.51%)

Over a week ago
Options
AstraZeneca call volume above normal and directionally bullish » 10:05
06/26/20
06/26
10:05
06/26/20
10:05
AZN

AstraZeneca

$53.31 /

+0.3 (+0.57%)

Bullish option flow…

Bullish option flow detected in AstraZeneca with 36,053 calls trading, 8x expected, and implied vol increasing almost 2 points to 39.85%. Aug-20 65 calls and Jul-20 60 calls are the most active options, with total volume in those strikes near 28,300 contracts. The Put/Call Ratio is 0.01. Earnings are expected on July 30th.

ShowHide Related Items >><<
AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

AZN AstraZeneca
$53.31 /

+0.3 (+0.57%)

Options
Unusually active option classes on open June 26th » 09:40
06/26/20
06/26
09:40
06/26/20
09:40
GPS

Gap

$10.17 /

+ (+0.00%)

, ZGNX

Zogenix

$28.12 /

+ (+0.00%)

, XBI

SPDR S&P BIOTECH

$114.18 /

+ (+0.00%)

, AZN

AstraZeneca

$53.01 /

+ (+0.00%)

, GS

Goldman Sachs

$207.37 /

+ (+0.00%)

, CLDR

Cloudera

$13.13 /

+ (+0.00%)

, NOK

Nokia

$4.45 /

+ (+0.00%)

, SONO

Sonos

$13.99 /

+ (+0.00%)

, SPOT

Spotify

$267.47 /

+ (+0.00%)

, AMZN

Amazon.com

$2,755.00 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Gap (GPS), Zogenix (ZGNX), SPDR S&P Biotech (XBI), AstraZeneca (AZN), Goldman Sachs (GS), Cloudera (CLDR), Nokia (NOK), Sonos (SONO), Spotify (SPOT), and Amazon (AMZN).

ShowHide Related Items >><<
ZGNX Zogenix
$28.12 /

+ (+0.00%)

SPOT Spotify
$267.47 /

+ (+0.00%)

SONO Sonos
$13.99 /

+ (+0.00%)

NOK Nokia
$4.45 /

+ (+0.00%)

GS Goldman Sachs
$207.37 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

CLDR Cloudera
$13.13 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

06/26/20 KeyBanc
Gap partnership with Kanye West should help with younger shoppers, says KeyBanc
06/22/20 Wells Fargo
Gap rallies after Wells double upgrade on 'compelling value unlocks'
06/08/20 Deutsche Bank
Gap price target lowered to $13 from $15 at Deutsche Bank
06/05/20 MKM Partners
Gap price target raised to $12 from $8 at MKM Partners
ZGNX Zogenix
$28.12 /

+ (+0.00%)

06/26/20 Stifel
FDA approval of Fintepla provides 'sigh of relief' for Zogenix, says Stifel
05/05/20 Piper Sandler
Zogenix price target lowered to $56 from $64 at Piper Sandler
04/22/20 Piper Sandler
Zogenix Fintepla data supports broader utility, says Piper Sandler
04/01/20 Mizuho
Zogenix price target lowered to $64 from $71 at Mizuho
XBI SPDR S&P BIOTECH
$114.18 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
GS Goldman Sachs
$207.37 /

+ (+0.00%)

06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
06/03/20 Deutsche Bank
Wells Fargo upgraded to Buy, Goldman Sachs cut to Hold at Deutsche Bank
CLDR Cloudera
$13.13 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley says Cloudera could be valued at $14.50 using typical PE multiple
06/09/20 DA Davidson
DA Davidson says Cloudera sale 'increasingly likely,' IBM seen as possible buyer
06/09/20 Northland
Northland downgrades Cloudera to Market Perform as coverage transferred
06/03/20
Fly Intel: Top five analyst upgrades
NOK Nokia
$4.45 /

+ (+0.00%)

06/25/20 Deutsche Bank
Nokia price target raised to EUR 4.80 from EUR 4 at Deutsche Bank
06/01/20 JPMorgan
JPMorgan upgrades Nokia to Overweight with 5G cycle 'just starting'
06/01/20 JPMorgan
Nokia upgraded to Overweight from Neutral at JPMorgan
05/05/20 Deutsche Bank
Nokia price target raised to EUR 4 from EUR 3.80 at Deutsche Bank
SONO Sonos
$13.99 /

+ (+0.00%)

06/24/20 Raymond James
Sonos job cuts not based on recent trends, says Raymond James
06/11/20 Morgan Stanley
Morgan Stanley recommends Overweight Sonos, Underweight GoPro pair trade
04/21/20 Raymond James
Sonos Radio could drive 'meaningfully higher' multiples, says Raymond James
04/17/20 Goldman Sachs
Sonos downgraded to Sell from Buy at Goldman Sachs
SPOT Spotify
$267.47 /

+ (+0.00%)

06/25/20 Goldman Sachs
Spotify price target raised to $280 from $205 at Goldman Sachs
06/19/20 Rosenblatt
Spotify price target raised to $275 from $190 at Rosenblatt
06/19/20 Monness Crespi
Spotify price target raised to $275 from $200 at Monness Crespi
05/28/20
Fly Intel: Top five analyst downgrades
AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

06/26/20 SunTrust
Etsy price target raised to $112 from $88 at SunTrust
06/26/20 SunTrust
Amazon.com price target raised to $3,400 from $2,700 at SunTrust
06/26/20 Deutsche Bank
Amazon.com price target raised to $3,333 from $2,750 at Deutsche Bank
06/24/20 Raymond James
Amazon live TV would further differentiate Prime Video, says Raymond James
ZGNX Zogenix
$28.12 /

+ (+0.00%)

SPOT Spotify
$267.47 /

+ (+0.00%)

SONO Sonos
$13.99 /

+ (+0.00%)

NOK Nokia
$4.45 /

+ (+0.00%)

GS Goldman Sachs
$207.37 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

CLDR Cloudera
$13.13 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

  • 18
    Jun
  • 04
    Mar
ZGNX Zogenix
$28.12 /

+ (+0.00%)

SPOT Spotify
$267.47 /

+ (+0.00%)

SONO Sonos
$13.99 /

+ (+0.00%)

NOK Nokia
$4.45 /

+ (+0.00%)

GS Goldman Sachs
$207.37 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

CLDR Cloudera
$13.13 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

ZGNX Zogenix
$28.12 /

+ (+0.00%)

SPOT Spotify
$267.47 /

+ (+0.00%)

SONO Sonos
$13.99 /

+ (+0.00%)

NOK Nokia
$4.45 /

+ (+0.00%)

GS Goldman Sachs
$207.37 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

CLDR Cloudera
$13.13 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

ZGNX Zogenix
$28.12 /

+ (+0.00%)

XBI SPDR S&P BIOTECH
$114.18 /

+ (+0.00%)

SPOT Spotify
$267.47 /

+ (+0.00%)

SONO Sonos
$13.99 /

+ (+0.00%)

NOK Nokia
$4.45 /

+ (+0.00%)

GS Goldman Sachs
$207.37 /

+ (+0.00%)

GPS Gap
$10.17 /

+ (+0.00%)

CLDR Cloudera
$13.13 /

+ (+0.00%)

AZN AstraZeneca
$53.01 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

XBI SPDR S&P BIOTECH
$114.18 /

+ (+0.00%)

AMZN Amazon.com
$2,755.00 /

+ (+0.00%)

Hot Stocks
AstraZeneca says Phase III ETHOS results show reduced rate of COPD exacerbations » 14:27
06/24/20
06/24
14:27
06/24/20
14:27
AZN

AstraZeneca

$52.24 /

-2 (-3.69%)

Full results from the…

Full results from the positive Phase III ETHOS trial showed AstraZeneca's triple-combination therapy Breztri Aerosphere demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease. Compared with Bevespi Aerosphere, Breztri Aerosphere achieved a 24% reduction in exacerbations. Breztri Aerosphere achieved a 13% reduction compared with PT009 (budesonide/formoterol fumarate). The dual-combination therapies used as comparators in the trial represent recommended therapeutic classes for the treatment of COPD. In a key secondary endpoint, Breztri Aerosphere showed a 46% reduction in the risk of all-cause mortality compared with Bevespi Aerosphere. The results were published in the New England Journal of Medicine1 and simultaneously presented at the American Thoracic Society virtual Scientific Symposium, Clinical Trial Results in Pulmonary Medicine.3 AstraZeneca will continue to review these data with health authorities.

ShowHide Related Items >><<
AZN AstraZeneca
$52.24 /

-2 (-3.69%)

AZN AstraZeneca
$52.24 /

-2 (-3.69%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$52.24 /

-2 (-3.69%)

AZN AstraZeneca
$52.24 /

-2 (-3.69%)

AZN AstraZeneca
$52.24 /

-2 (-3.69%)

AZN AstraZeneca
$52.24 /

-2 (-3.69%)

Downgrade
AstraZeneca downgraded to Reduce from Buy at Oddo BHF » 06:14
06/24/20
06/24
06:14
06/24/20
06:14
AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

Oddo BHF analyst…

Oddo BHF analyst Sebastien Malafosse downgraded AstraZeneca to Reduce from Buy with a 7,600 GBp price target.

ShowHide Related Items >><<
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 05:55
06/24/20
06/24
05:55
06/24/20
05:55
A

Agilent

$89.36 /

+0.81 (+0.91%)

, ABBV

AbbVie

$97.28 /

+0.03 (+0.03%)

, ADPT

Adaptive Biotechnologies

$46.95 /

+1.04 (+2.27%)

, AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$187.74 /

+4.42 (+2.41%)

, BMY

Bristol-Myers

$58.41 /

+0.85 (+1.48%)

, BNTX

BioNTech

$52.80 /

-4.64 (-8.08%)

, CRL

Charles River

$175.05 /

-0.12 (-0.07%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.33 /

+0.26 (+0.31%)

, GILD

Gilead

$75.01 /

-0.61 (-0.81%)

, PFE

Pfizer

$32.78 /

-0.33 (-1.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVCR

Novocure

$62.71 /

-0.31 (-0.49%)

, NTRA

Natera

$46.65 /

+0.36 (+0.78%)

, SNY

Sanofi

$52.49 /

-0.06 (-0.11%)

, RUBY

Rubius Therapeutics

$6.52 /

-0.02 (-0.31%)

, NEO

NeoGenomics

$29.05 /

+0.49 (+1.72%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.06 /

-0.75 (-2.91%)

, QGEN

Qiagen

$42.87 /

+0.31 (+0.73%)

, LLY

Eli Lilly

$159.35 /

-1.06 (-0.66%)

, PKI

PerkinElmer

$99.11 /

+1.08 (+1.10%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

, ILMN

Illumina

$367.22 /

+7.02 (+1.95%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

A Agilent
$89.36 /

+0.81 (+0.91%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

06/23/20
Fly Intel: Top five analyst upgrades
06/23/20 Atlantic Equities
AbbVie upgraded to Overweight from Neutral at Atlantic Equities
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/23/20 Berenberg
Bayer price target raised to EUR 86 from EUR 82 at Berenberg
06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.05 /

-0.12 (-0.07%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.33 /

+0.26 (+0.31%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.01 /

-0.61 (-0.81%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$32.78 /

-0.33 (-1.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$62.71 /

-0.31 (-0.49%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.65 /

+0.36 (+0.78%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
ILMN Illumina
$367.22 /

+7.02 (+1.95%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.